【英文名】visceralleishmaniasis 【缩写】 【别名】blacksickness;Burdwanfever;kala-azar;黑热病;内脏利什曼 原虫病 【ICD号】B55.0 【概述】 利什曼病(leishmaniasis)系利什曼原虫所引起的寄生虫病,由不同虫种引 起的利什曼病的临床表现也不同,可分为内脏利什曼病(visceral ...
Visceral leishmaniasis (VL), an emerging and sustainable fatal disease, claims significant proportion of lives predominantly in the marginalised areas of developing countries. The impact of existing interventions to control the disease is insufficient. Epidemics and resurgence of the disease can be ...
Read full chapterView PDFExplore book MOTH FLIES AND SAND FLIES (Psychodidae) LOUIS C.RUTLEDGE,RAJ K.GUPTA, inMedical and Veterinary Entomology, 2002 Visceral Leishmaniasis Visceralleishmaniasisis also known askala-azar(from the Hindi for “black fever”) anddumdum fever(from Dum Dum, the locati...
Bal AM (2005) Visceral leishmaniasis—an opportunistic infection in HIV infected patients. Lancet Infect Dis 5:196–197Bal AM. Visceral leishmaniasis--an opportunistic infection in HIV-infected patients. Lancet Infect Dis 2005; 5: 196-197....
Visceralleishmaniasis: Dot-enzyme immunoassay; Circulating antigen 1.Introduction Visceralleishmaniasis (VL)isadiseasecausedby Abbreviations: VL,visceralleishmaniasis:EIA,enzyme im- munoassay; MAb.monoclonal antibody; CL.cutaneous leishma- niasis:OD,opticaldensity;PBS,phosphate buffered saline. ICorresponding...
et al. Visceral Leishmaniasis Presenting as Subcutaneous Nodules in a HIV-Positive Patient. Eur J Clin Microbiol Infect Dis 22, 329–331 (2003). https://doi.org/10.1007/s10096-003-0923-5 Download citation Published08 May 2003 Issue DateMay 2003 DOIhttps://doi.org/10.1007/s10096-003-0923...
Objective: The aim of the present review was to close the gap in the approach to pregnant women with visceral leishmaniasis (kala-azar) by providing up-to-date information to obstetricians about phys...
Combination therapy is the suggested way forward to increase treatment efficacy, prevent the develop- ment of drug resistance, reduce treatment duration and Box 3 | Questions raised by the VL elimination programme • What are the best ways to monitor the incidence of visceral leishmaniasis (VL)...
Visceral Leishmaniasis in the Developing World Gilead Sciences is committed to supporting global efforts to control and eliminate visceral leishmaniasis (VL), a parasitic infectious disease that predominantly affects people in developing world countries. AmBisome® is a World Health Organization (WHO)...
Visceral leishmaniasis (VL), a deadly parasitic disease, is a major public health concern globally. Countries affected by VL have signed the London Declaration on Neglected Tropical Diseases and committed to eliminate VL as a public health problem by 2020. To achieve and sustain VL elimination, ...